news

Sm@rt model:sv4 reset

Sm@rt model:sv4 reset





Valid till 2017/5/25



6AVCPBH0 WINCC SM@RT SERVER FOR PANELS, LK DL SIMATIC WinCC SM@RT Server for SIMATIC Panels FAQ How do you reset a personal password in OSD if. Order C&K RSG05A3-SM RT (CKNCT-ND) at DigiKey. Check stock and pricing, view product specifications, and order online. Charles Schwab offers a wide range of investment advice, products & services, including brokerage & retirement accounts, ETFs, online trading & more.
A monstrous, brown, leathery, alien entity native to a mysterious Model:sv4, currently slumbering within a gigantic mausoleum lost in the desert-wastes, set to guard a Reset treasure made up of the oldest decayed planets. The association complex of claimfurther comprising a structural moiety and a Model:sv4 lipid, wherein the ratio, by weight, of preparation of claim 1 or claimstructural moiety, PEGylated lipid, and a nucleic acid, is Insulin-like Reset factor binding protein, acid labile subunit igfals and insulin-like growth factor 1 igf-1 irna compositions and methods of use thereof. The preparation of claimwherein Sm@rt R Sm@rt. Klin Padiatr ; This Mythos entity is somewhat inspired by C.
6AVCPBH0 WINCC SM@RT SERVER FOR PANELS, LK DL SIMATIC WinCC SM@RT Server for SIMATIC Panels FAQ How do you reset a personal password in OSD if. Order C&K RSG05A3-SM RT (CKNCT-ND) at DigiKey. Check stock and pricing, view product specifications, and order online. Charles Schwab offers a wide range of investment advice, products & services, including brokerage & retirement accounts, ETFs, online trading & more.

sm@rt model:sv4 reset

sm@rt model:sv4 reset

sm@rt model:sv4 reset

sm@rt model:sv4 reset

sm@rt model:sv4 reset

sm@rt model:sv4 reset

sm@rt model:sv4 reset

sm@rt model:sv4 reset

Free reset sm@rt model:sv4 and test

Alwx;3 arid DSC, R moieties are Tgot fi. A three-eyed, gilled, proboscidian monster with a globular torso, six, long sinuous limbs ending in black paws, with crab – like claws, and covered in what appears to be hair, but is actually tiny tentacles. Telomestatin suppresses cellular proliferation and induces apoptosis within a few days in various cancer cells but not in normal cells Because indiscriminate binding of a compound to nonspecific DNA can result in significant loss of the compound and may have unintentional effects on the regulation of nontargeted genes, we investigated the binding ability of S2TOTD to duplex DNA. Cornpound 22 4,75g, 6. The preparation of claim 61, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene.

The preparation of claim 44, wherein Y is NH. The preparation of claim 44, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene. The preparation of claim 44, wherein m is 2.

The preparation of claim 52, wherein Y is O. The preparation of claim 52, wherein Y is NH. The preparation of claim 52, wherein R1 is alkyl. The preparation of claim 55, wherein R1 is C alkyl.

The preparation of claim 56, wherein R1 is C12 alkyl. The preparation of claim 58, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene. The preparation of claim 52, wherein m is 2.

The preparation of claim 61, wherein R1 is alkyl. The preparation of claim 62, wherein R1 is C alkyl. The preparation of claim 63, wherein R1 is C12 alkyl. The preparation of claim 61, wherein Y is O.

The preparation of claim 61, wherein Y is NH. The preparation of claim 61, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene. The preparation of claim 61 , wherein m is 2. The preparation of claim 69, wherein Y is O.

The preparation of claim 69, wherein Y is NH. The preparation of claim 69, wherein R1 is alkyl. The preparation of claim 72, wherein R1 is C alkyl. The preparation of claim 73, wherein R1 is C12 alkyl.

The preparation of claim 69, wherein n is 2. The preparation of claim 69, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene. The preparation of claim 69, wherein m is 2.

The preparation of claim 78, wherein R1 is alkyl. The preparation of claim 79, wherein R1 is C alkyl. The preparation of claim 80, wherein R1 is C12 alkyl. The preparation of claim 78, wherein Y is O.

The preparation of claim 78, wherein Y is NH. The preparation of claim 78, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene. The preparation of claim 78, wherein m is 2.

The preparation of claim 1, wherein n is 0 and X is propylene. The preparation of claim 86, wherein 1 R is H. The preparation of claim 86, wherein when R is not H, R is R a. The preparation of claim 86, wherein R1 is alkyl.

The preparation of claim 89, wherein R1 is C alkyl. The preparation of claim 90, wherein R1 is C12 alkyl. The preparation of claim 86, wherein Y is O. The preparation of claim 86, wherein Y is NH.

The preparation of claim 86, wherein m is 2. The preparation of claim 95, wherein Y is NH. The preparation of claim 98, wherein R is R a, for 5 occurrences. The preparation of claim, wherein Y is NH.

The preparation of claim 95, wherein the compound of formula I is an inorganic or organic salt thereof. The preparation of claim, wherein the compound of formula I is a hydrohalide salt thereof.

The preparation of claim, the compound of formula I is a hydrochloride salt thereof. The preparation of claim 1, comprising a hydrate of the compound of formula I.

The preparation of claim 1, wherein the compound of formula I is salt of an organic acid. The preparation of claim, wherein the salt is an acetate. The preparation of claim, wherein the salt is an formate.

The preparation of claim 1, wherein R1 comprises an alkenyl moiety. The preparation of claim, wherein R1 comprises a cis double bond. The preparation of claim 1, the preparation comprising a plurality of compounds of formula I.

The preparation of claim, the preparation comprising a mixture of compounds of the formulas below: The preparation of claim, wherein formula I’ and I” and present in a ratio of from about 1: A method of making a compound of formula II, wherein each X a and X b, for each occurrence, is independently C alkylene; n is 0, 1, 2, 3, 4, or 5; and wherein each R is independently H or m is 2; Y is O, NR2, or S; R1 is alkyl or alkenyl; R2 is H or C alkyl or alkenyl; the method comprising reacting a compound of formula III with a compound of formula IV, in the presence of a promoter.

A method of making a compound of formula II, wherein each X a and X B, for each occurrence, is independently C alkylene: A method of making a compound of formula II, wherein each Xa and Xb, for each occurrence, is independently C alkylene; n is 0,1,2,3,4, or 5; and wherein each R is independently H or m is 2; Y is O, NR2, or S; R1 is alkyl or alkenyl; R2 is H or alkyl or a1kenyl; the method comprising reacting a compound of formula III with a compound of formula IV, wherein the reaction mixture comprises from about 0.

The method of claim, wherein the reaction mixture comprises from about 0. The method of claim, wherein the reaction mixture comprises about 1 molar equivalents of a compound of formula III, with from about 6 molar equivalents of a compound of formula IV.

The method of claim, wherein the reaction mixture comprises about 1 molar equivalents of a compound of formula III, with from about 5 molar equivalents of a compound of formula IV.

A method of making a compound of formula II, wherein each Xa and Xb, for each occurrence, is independently C alkylene; n is 0,1,2,3,4, or 5; and wherein each R is independently H or m is 2; Y is O, NR2 or S; R1 is alkyl or alkenyl; R2 is H or alkyl or alkenyl; the method comprising a two Step process of reacting a compound of formula III with a compound of formula IV, in the presence of boric acid and water wherein, the first step process involving the reaction mixture comprises from about 0.

A method of making a compound of formula Il, wherein each X a and X b, for each occurrence, is independently C alkylene; n is 0,1,2,3,4, or 5: The method of claim, wherein the chromatographic separation is using flash silica for separation of isomers.

The method of claim, wherein the chromatographic separation is gravity separation of isomers using silica gel. The method of claim, wherein the chromatographic separation is using moving bed chromatagraphy for separation of isomers.

The method of claim, wherein the chromatographic separation is using liquid chromatagraphy LC for separation of isomers. The method of claim, wherein the chromatographic separation using is normal phase HPLC for separation of isomers.

The method of claim, wherein the chromatographic separation is using reverse phase HPLC for separation of isomers. A method of making a compound of formula V or a pharmaccutically acceptable salt thereof, wherein each X a and X b, for each occurrence, is independently C alkylene; n is 0,1,2,3,4,or 5; and wherein each R is independently H or m is 1; Y is O, NR2, or S; R1 is alkyl or alkenyl; R2 is H or alkyl or alkenyl; the method compromising reacting a compound of formula III with a compound of formula VI, to provide a compound of formula V or a pharmaceutically acceptable salt thereof.

The method of claim, wherein the pharmaceutically acceptable salt thereof is a hydrochloride salt of the compound formula of the V. The compound of claim, wherein the compound is an inorganic salt thereof.

The compound of claim, wherein the compound is a hydrohalide salt thereof. The compound of claim, wherein the compound is a hydrochloride salt thereof.

The compound of claim, wherein the compound is an organic salt thereof. The compound of claim, wherein R1 and R2 are each independently C1-C3 alkyl. The compound of claim, wherein R1 is methyl. The compound of claim, wherein R2 is methyl.

The compound of claim, wherein R1 and R3 are both methyl. The compound of claim, wherein R1 is H, methyl, ethyl, isopropyl, or 2-hydroxyethyl. The compound of c1aim, wherein R2 is H.

The compound of claim, wherein R2 is ethyl. The compound of claim, wherein R2 is propyl. The compound of claim, wherein R2 is isopropyl. The compound of claim, wherein R2 is H, methyl, ethyl, propyl, or isopropyl.

The compound of claim, wherein R1 is H, methyl, ethyl, isopropyl, or 2-hydroxyethyl and R2 is H, methyl, ethyl, propyl, or isopropyl. The compound of claim, wherein m is 1.

The compound of claim, wherein n is 1. The compound of claim, wherein both m and n are 1. The compound of claim, wherein L1 is S-S-. The compound of claim, wherein L2 is S-S-.

The compound of claim, wherein both L1 and L2 are S-S-. The compound of claim, wherein L1-R3 and L2-R4 are taken together to form an acetal, a ketal, or an orthoester. The compound of claim, wherein each R3 and R4 are independently alkyl.

The compound of claim, wherein both R3 and R4 are C6-C28 alkyl. The compound of claim, wherein R3 is alkyl. The compound of claim, wherein R4 is alkyl. The compound of claim, wherein R3 is alkenyl.

The compound of claim, wherein R4 is alkenyl. The compound of claim, wherein each R3 and R4 are independently alkenyl. The compound of claim, wherein each R3 and R4 are independently C6-C30 alkenyl.

The compound of claim, wherein each R3 and R4 are the same alkenyl moiety. The compound of claim, wherein each R3 and R4 includes two double bond moieties. The compound of claim, wherein at least one of the double bonds have a Z configuration.

The compound of claim, wherein both of the double bonds have a Z configuration. The compound of claim, wherein at least one of R3 and R4 is provided in formula II below wherein x is an integer from 1 to 8; and y is an integer from The compound of claim, wherein both of R3 and R4 are of the formula II.

The compound of claim, wherein at least one of the double bonds have an E configuration. The compound of claim, wherein both of the double bonds have an E configuration.

The compound of claim, wherein at least one of R1 and R2 is provided in formula III below wherein x is an integer from 1 to 8; and y is an integer from The compound of claim, wherein each R1 and R2 includes three double bond moieties.

The compound of claim, wherein at least two of the double bonds have a Z configuration. The compound of claim, wherein all three of the double bonds have a Z configuration. The compound of claim, wherein at least one of R1 and R2 is provided in formula IV below wherein x is an integer from 1 to 8; and y is an integer from 1 The compound of claim, wherein both of R1 and R2 are as provided in formula IV.

The compound of claim, wherein at least two of the double bonds have an E configuration. The compound of claim, wherein all three of the double bonds have an E configuration.

The compound of claim, wherein at least one of R1 and R2 is provided in formula IV below formula V wherein x is an integer from 1 to 8; and y is an integer from The compound of claim, wherein both of R1 and R2 are as provided in formula V.

A preparation comprising a compound of formula X. The method of claim, wherein the coupling agent is a carbodiimide. The method of claim, wherein the coupling reagent is EDCI.

A method of forming an association complex comprising contacting a lipid preparation of claim 1 or claim with a therapeutic agent in the presence of a buffer, wherein said buffer: An association complex made by the method of claim The method of claim, wherein the particle has a diameter of less than about 50 uM.

A method of forming an association complex comprising contacting a lipid preparation of claim 1 or claim with a therapeutic agent in the presence of a buffer, wherein said buffer has a concentration from about to about mM.

An association complex comprising a preparation of claim 1 or claim and a nucleic acid. The association complex of claim, further comprising a PEGylated lipid. The association complex of claim, further comprising a structural moiety.

The association complex of claim, wherein the structural moiety is cholesterol. The association complex of claim, wherein said nucleic acid is an siRNA. The association complex of claim, wherein said nucleic acid is an siRNA which has been modified to resist degradation.

The association complex of claim, wherein said nucleic acid is an siRNA which has been modified by modification of the polysaccharide backbone. The association complex of claim, wherein the siRNA targets a gene or genes of interest.

The association complex of claim, wherein the gene or genes of interest is an endogeneously expressed gene in liver. The association complex of claim, wherein the gene of interst is apoB.

The association complex of claim, wherein the gene of interest is FVII. The association complex of claim, wherein the gene of interest is PCSK9. The association complex of claim, wherein the gene of interest is VEGF.

The association complex of claim, wherein the gene of interest is KSP eg5. The association complex of claim, wherein the gene of interest is hepcidin.

The association complex of claim, wherein the gene of interest is HCV. The association complex of claim, wherein said nucleic acid is a single stranded nucleic acid or derivatives thereof.

The association complex of claim, wherein the nucleic acid is an antisense nucleic acid. The association complex of claim, wherein the nucleic acid is a microRNA. Appears as a huge winged octopus – like creature with six eyes.

Youngest of Cthulhu and Idh-yaa’s progeny. Appears as a gigantic black mass of tentacles, with a single green eye at the center. A serpentine likely Tremors – like earth-shaking horror dwelling in the subsoil of Memphis, US.

The Dweller in the Gulf. Appears as a huge, eyeless, black, soft-shelled tortoise with a triangular head, two whip-like tails, and suckers on the end of each tail.

A jewel-facetted, semi-crystalline geode with mineral tentacles. A gigantic saurian creature similar to Bokrug, but terrestrial, and endowed with a mane of tentacles. A ravenous plant-god who arrived from Xiclotl to Earth, awed by the Insects from Shaggai.

He appears as a white orb hiding an enormous magenta excrescence, like an orchid or a lamprey – like mouth, with emerald tentacles, tipped with hands emerging from within the hideous mass.

Appears as a huge, pallid, gelatinous oval with a myriad of legs and multiple eyes. Lord of the Volcano, Thoa [35]. Appears as a colossal horror with multifarious appendages, and Gorgon – like powers.

A cosmic-entity manifesting as a gigantic, spongy, and fleshy mass covered in a myriad of both eyes and spines. He is said to be the nemesis of the Outer God Uvhash, usually summoned to contrast this deity.

Appears as a giant three-eyed slug with metallic spines, and tiny pyramid-like feet underneath. Usually manifests through a Dionysian sculpture, but its true form is that of a gigantic wattled slug – thing.

Appears as a colossal pillar of amorphous alien flesh, with a cyclopean head. It drags up the continent it is summoned in, and causes the entire world to suddenly cave-in on itself.

A vaporous red entity haunting the rainforest of Central Africa. It has the power to turn humans into zombie – like servants, the Tree-Men of M’bwa. A gigantic entity dwelling in some reverse dimension, resembling a huge bullet with a long proboscis.

Appears as a gigantic, black, toad – like creature with an impossibly malevolent glare, or a tentacled, scaled, bat-winged entity. An entity cut in ten pieces by Yig during a time of great battle one of these pieces is an alabaster dish found in Egypt, dated back 1, BC.

It resembles and has a similar domain as the Greek god Bacchus. A sentient plant – like entity dwelling within a series of subterranean caverns, where it is always served by mutant rabbit-like worshipers.

A monstrous bird – like fiend with sharp teeth, dwelling beneath Antarctica, vaguely resembling an extinct pterosaur. A destructive entity manifesting as a ravenous metallic vortex.

He seems to be another half-brother of Cthulhu, like Hastur, and related to the slug-like Glaaki as well. He has also been called a “son of Yog-Sothoth “. Whether these titles are literal or conceal some dark truth about the Destroyer, none can ascertain.

He dwells somewhere in the Pleiades stellar region, and when summoned, he brings devastation. A shadowy incorporeal entity dwelling in the Dreamlands. A great shadow thing, with two glaring red eyes, able to transform the skull of its victims into green glowing stones carved with strange symbols.

A tentacled amoebic horror with multiple eyes, orifices, and a dangling gland forming a hideous face. His true form is unknown, but usually manifests either as a polypous, ravenous floating mass endowed with tentacles, drills, and suckers, or more frequently, as the King in Yellow, a humanoid being wearing tattered, yellow clothes and a mask hiding the face.

He is said to be Cthulhu ‘s half – brother. He is said to be of the air element opposed to Cthulhu’s water element. A towering greenish trunk with a “crown” of tentacles, a row of multiple eyes, and a series of additional lateral grasping appendages.

Lesser brother of Cthulhu, manifesting as a gigantic mouth surrounded by countless tentacles, similar to a titanic sea anemone. Has a spheroid body, elongated arms, short legs, and a pendulum – like head dangling underneath.

He is the brother of Ghisguth, and uncle of Tsathoggua. A gigantic, pale, worm – like horror dwelling beneath the crust of the star Xoth. She has been Cthulhu ‘s first bride, and with him spawned three sons – Ghatanothoa, Ythogtha, and Zoth-Ommog – and a younger daughter, Cthylla.

A levitating, sinuous glowing creature. A cat – like deity, similar to Bastet, but vicious and malignant. Her sister is the sylvan Lythalia. A gigantic, corpse-like human, with webbed feet and glowing red eyes.

A crustacean – like, tentacled, half-amorphous marine horror which serves Cthulhu, dwelling in the depths of the Bay of Rhiiklu, somewhere within the eastern coast of the United States.

The Ravenous One [40]. Likely a gigantic larva – like horror, dwelling in the nebulous realm of K’gil’mnon, along with the Gharoides, its parasitic insectoid servants.

Kag’Naru of the Air [41]. Mentioned in the American comic book Challengers of the Unknown as the sister of M’Nagalah. A huge mass of coiled, writhing tentacles. She is Cthulhu’s sister and mate, who bore him the twin daughters Nctosa and Nctolhu.

A squat, sea cucumber – like monstrosity with five eyes, three-toed, taloned appendages, and a large mouth. A dark octopoid horror, similar to the Norse Kraken, but dwelling inside a temple somewhere within a hidden warm valley in Alaska.

An amphibious humanoid with four, seven-clawed arms, and tentacles in place of legs. The head is lion-like, but bony and his mouth encases three long tongues.

He lies trapped beneath the seafloor, inside a mysterious seamount called Nayghof. A monstrous, brown, leathery, alien entity native to a mysterious planet, currently slumbering within a gigantic mausoleum lost in the desert-wastes, set to guard a priceless treasure made up of the oldest decayed planets.

The Supreme Unknown, Scourge of Yaksh. A six-eyed, crocodile-snouted monstrosity covered with both tentacles and tripod-like limbs. Revered by the ancient Egyptians as the deification of both darkness and chaos.

A giant hairless dingo – like fiend living in the Dreamlands or the Dreamtime of Aboriginal myths. An alien entity, similar to Grey aliens, dwelling in the dark side of the planet Mars.

A female seductive humanoid – entity, covered in both vines and vegetal parts. Somehow, she has been the mate of the Elder God Nodens, bearing him the twin gods Vorvadoss and Yaggdytha.

A dragon-like entity, covered in pseudopods, regarded as the mother of the Snake-God Yig and said to be imprisoned beneath the sunken continent of Mu.

A spider-eyed bat-winged horror lurking within the Congo River. The Devourer, The Cancer God [48]. A mass of both entrails and eyes, or a massive blob-thing. A very large and eyeless lizard – like creature with a “crown” of feelers.

Mormo appears in many forms, but three are most common: This last form is the appearance of her servitors, the Moon-beasts. A lustrous orb floating at the center of a whirling vortex of razor-sharp, metallic-looking blades.

A succubus – like fiend with alien traits, and tentacles in place of hair. They both appear as huge shell-endowed beings, with eight segmented limbs, and six long arms ending with claws, vaguely resembling their “half-sister” Cthylla.

A ferocious and towering wolf – like humanoid with bat wings. He is served by werewolf servants known as the Lupine Ones. A mysterious entity related to Yog-Sothoth, Shub-Niggurath, and possibly Azathoth as well which manifests either as a faun – like humanoid with color-changing hair, or as a glowing halo of unknown color.

A sort of gigantic pulsating heart secluded in a parallel dimensions. It is responsible for spawning all of the various monsters which exist within the known Universe.

Two horrid nebulous masses of shape-changing vapor from which eyes, tentacles, maws, and hooves emerge; somewhat like Shub-Niggurath. They have been spawned by Yog-Sothoth, and both or either are regarded as the blasphemous parents of Cthulhu.

The Kraken Within [55]. A blurry, dark, kraken – like entity mentioned in the Song of Yste, and said to dwell in Outer Space. A tall larva – like monstrosity, with hundreds of segmented taloned tendrils, exiled by the Elder Gods into a parallel dimension, with close connections to the rainforests of South America, where he lures human victims to enslave from other dimensions.

Formerly, he was too an Elder God. Appears as a huge, tentacled mollusk. A twisting tentacled mass, with a single alien face somewhere in the center of the slimy squirming mass.

A maddening, twisted-minded, alien entity appearing as a feminine figure in a red cloak, with three eyes, and an utterly alien face. Likely coincident with Classical Underworld goddess Persephone, she manifest aboard a ghost ship and contact traumatized humans, with hidden artistic talent, to spread both chaos and despair across the world.

A black, fanged, cycloptic demon with arms like swaying serpents. A tall humanoid with an eyeless sea anemone – like face, and a beaked grinning mouth, who can be summoned like a jinn.

A mysterious entity related to zoomorphic shapeshifters, especially were-cats. Appears as a miniature, wrinkled mummy with stiff, outstretched claws. Worshiped as a deity in a lost continent located in the southern Atlantic Ocean.

He appears related to Nyarlathotep, and his form is likely octopoid, with myriads of horns along a maddening body. A towering mass of crystals, residing on the lightless planet Mthura.

A shark – like humanoid native to the Bermuda Triangle, possibly similar to Cthulhu ‘s avatar the Father of All Sharks. The One from the Sun Race [63]. A fiery entity similar to Cthugha, able to absorb nuclear radiation, and imprisoned somewhere within the subsoil of New Mexico.

A three-eyed, gilled, proboscidian monster with a globular torso, six, long sinuous limbs ending in black paws, with crab – like claws, and covered in what appears to be hair, but is actually tiny tentacles.

Rh’Thulla of the Wind [41]. Mentioned in the American comic book Challengers of the Unknown as the brother of M’Nagalah. A gigantic, whitish worm with a huge maw and hollow eyes made of dripping globules of blood.

A mysterious extra-dimensional entity, regarded as the brother of Yig, ruling over a dimension called Zandanua. One of Hziulquoigmnzhah ‘s children, supposedly female.

A crocodile – headed reptilian humanoid, equal to the Ancient Egyptian god Sobek. A colossal glowing worm, with a starfish – shaped head, dwelling in Antarctica and served by the Mi-go.

The granddaughter of Tsathoggua, an amorphous mass which mated with a Hyperborean Voormi and spawned the legendary thief Knygathin Zhaum. A dark-skinned humanoid horror with tentacles sprouting from his head, and glowing red eyes, worshiped by the earliest African civilizations as the god Amun.

He is said to be rival of Cthulhu. Morton [66] as a descendant of Cthulhu which spawned other two horrid descendants K’baa the Serpent and Ghoth the Burrower. The latter would have sired with a Roman noblewoman Viburnia the legendary ancestor of Lovecraft himself in a fictional family tree.

The appearance of Shaurash-Ho has never been described. A shape-shifting entity, often manifesting as a spiny five-legged crab, with a spider-like head and metallic bracelets on each limb.

A dark smoky column, with red malevolent eyes and a grotesque face, imprisoned inside a vintage box. A starfish-like horror spawned by the Outer God C’thalpa. Aberrant c-Myc signaling has been observed in human cancers, and c-Myc has been shown to promote cell transformation and tumor progression 29 — Furthermore, high c-Myc mRNA expression was shown to be significantly associated with tumor anaplasia 44 , D and D MB cells were the kind gift of Dr.

Rat fibroblast cells HO PC12 cells were cultured in complete growth medium with FBS to a final concentration of 2. Cell lines that were not purchased from the American Type Culture Collection in were tested for their authentication by karyotypic analysis using molecular cytogenetic techniques, such as comparative genomic hybridization.

PCR-stop assay was done as previously reported The mixtures were incubated in a thermocycler under the following conditions: The IC 50 values were calculated based on the fluorescence intensity scanned with a phosphorimager Typhoon, Molecular Dynamics.

Circular dichroism CD experiments were carried out with a Jasco J instrument equipped with a computer-controlled water thermostat. Optical path length was 1 mm.

Experiments were done in triplicate for each data point. Membranes were then washed thrice at room temperature, and bound immunoglobulin was detected with anti-isotype monoclonal antibody coupled to horseradish peroxidase Santa Cruz Biotechnology.

The signal was visualized by enhanced chemiluminescence Amersham Biosciences and autoradiography. Relative band intensities were determined using Quantity One analysis software Bio-Rad.

The cell suspension was incubated for 30 min at room temperature, and cell cycle distribution was determined by flow cytometry FACSCalibur, Becton Dickinson, with CellQuest software analysis and quantification using ModFit software as described previously Cells were then cultured for 4 d and then trypsinized and counted.

Results were expressed as the cumulated population doublings as a function of the time of culture, as described by Binz et al. For cytotoxicity assay, cell viability was quantified using a colorimetric MTS assay Promega as previously described 47 , Each condition was done in triplicate.

All samples were assayed in triplicate. Student’s t test was used to test statistical significance. S1B and high-resolution mass spectrometry Supplementary Fig. No significant inhibition was observed when ss-Pu22 mutant containing a mutation in two guanine repeats into aniline was used data not shown.

C, quantification of the band absorbance fluorescence intensity by using phosphorimager. Points, mean of three independent experiments; bars, SD. PCR-inhibitory activities were calculated by the following equation: Figure 2A shows that, under our experimental conditions, the c-Myc G-quadruplex—forming sequence exhibited the typical spectral signature of a G-quadruplex with a characteristic maximum at nm 55 , In the presence of a five-times molar excess of S2TOTD, the peak centered at nm was significantly broader, with lower ellipticity at the maximum.

However, the spectral differences were not large enough to permit titration experiments to calculate the binding constant. Thermodynamic stability profiling provides information about the relative stability of DNA structures on ligand binding Therefore, the stabilization effect of S2TOTD on the G-quadruplex structure in the c-Myc promoter sequence was further studied by CD spectroscopy by measuring the thermodynamic stability profile of the ss-Pu22 oligomer and the change in absorption at nm.

The results in Fig. Because indiscriminate binding of a compound to nonspecific DNA can result in significant loss of the compound and may have unintentional effects on the regulation of nontargeted genes, we investigated the binding ability of S2TOTD to duplex DNA.

The results of these two experiments not only indicates that S2TOTD by itself has no significant inhibitory effect on the PCR but also confirms that S2TOTD possesses a direct effect on telomerase activity when examined in cell-free system data not shown.

To further confirm the requirement of the G-quadruplex—forming NHE III1 sequence in the promoter region of c-Myc for the exertion of downregulation of c-Myc expression by S2TOTD, two Burkitt’s lymphoma cell lines with different translocation break points within the c-Myc promoter 17 , 59 , 60 were investigated Supplementary Fig.

To determine the possible effects of S2TOTD on cell cycle regulation, we assessed the cellular DNA content by using flow cytometry fluorescence-activated cell sorting and determined CDK2 protein expression.

Moreover, treatment with S2TOTD resulted in a significant decrease in the percentage of cells that were able to enter the S phase and in an increase of the cells in the G 0 – G 1 and sub-G 1 phases Fig.

B, effects of S2TOTD on cell cycle in human brain tumor cells as determined by fluorescence-activated cell sorting analysis. At least 20, cells were counted. Results are presented as percentages of cells in G 1 , S, G 2 – M, and sub-G 1 phases in two independent experiments.

The subdiploid peak represents the apoptotic fraction. S2TOTD treatment resulted in a decrease in the percentage of cells in the S phase and an increase in the cells in the G 0 – G 1 and sub-G 1 phases in all cell lines tested.

Treatment with S2TOTD resulted in a dose – and time-dependent cytotoxic response in all cell lines tested, with IC 50 concentrations between 0. These cells do not depend on c-Myc to proliferate due to the absence of Max, the partner protein to which c-Myc dimerizes to be activated Fig.

We then characterized the growth properties of the treated cells during the long-term cultivation experiments. The morphologic examination of the 0. Finally, the cells underwent delayed apoptosis when examined morphologically data not shown and were characterized by an increase in apoptotic cell death, as measured by Cell Death Detection ELISA Fig.

Every 5 d, the cells were trypsinized and living cells were reseeded at the same number. A, effect of 0. All cell lines tested showed time-dependent telomere shortening.

B, effect of 0. All cell lines tested showed time-dependent decrease in cell growth. In this study, we investigated the efficiency of S2TOTD to stabilize G-quadruplexes in guanine-rich DNA and examined the strength of its selectivity for the c-Myc over the telomeric sequences.

We have shown here that S2TOTD binds more selectively with higher affinity to the G-quadruplex—forming sequence in the major transcription control element in the c-Myc promoter than to the telomeric DNA sequence.

This high-affinity physical interaction was established by the results obtained from the PCR-stop assay, which showed that a fold higher concentration of S2TOTD is needed to stabilize a G-quadruplex structure in ss-Telo24 compared with ss-Pu22 sequence.

This result was further confirmed by the CD spectroscopy experiments, which showed that the G-quadruplex structure stabilization by S2TOTD in the c-Myc promoter tolerated a higher thermal melting point compared with the telomeric DNA sequence.

The preference of a compound for quadruplexes over duplex DNA is of great importance. This is because indiscriminate binding to a duplex DNA can result in a significant loss of the compound and might lead to unexpected cytotoxicity.

These results therefore provided convincing evidence that the effect of S2TOTD on c-Myc is indeed mediated through the interaction with the c-Myc promoter and further implicated effects on c-Myc —dependent downstream pathways.

However, it has to be said that mechanisms regulating c-Myc transcription are multifaceted and involve not only the regulatory DNA sequence in c-Myc promoter but also several DNA binding proteins that have been shown to preferentially bind to, stabilize, unwind, or cleave the c-Myc G-quadruplex structure 66 — Hence, it could be speculated that any mutation in the regulatory motifs, differences in DNA binding protein expression patterns, or off-target ligand interaction might be critical for the sensitivity toward G-quadruplex—based c-Myc inhibitor, such as S2TOTD, in some cell lines, and their effect might present a different profile of biological activity than initially expected.

Based on previously published work, it is well established that the suppression of c-Myc expression is closely linked to the specific arrest in the G 0 – G 1 cell cycle phase 69 — 72 and downregulation of c-Myc inhibits both cyclins and CDK2 expression in rhabdomyosarcoma 73 , in T lymphocytes 74 , and in colorectal cancer cells Our results show that under the conditions where inhibition of both proliferation and c-Myc activity was observed, S2TOTD treatment resulted in a decrease in the protein expression of the cell cycle activator CDK2 and in a clear G 0 – G 1 cell cycle arrest in all brain tumor cell lines tested and decreased the percentage of the cells that were able to enter the S phase.

These results suggest that inhibition of c-Myc expression by S2TOTD may not be the only mechanism explaining the G 0 – G 1 arrest of the cell cycle and the cell growth inhibition, but the expression level of other oncogenes may be affected with an effect on downstream signaling pathways governing cell proliferation.

Many experimental lines of evidence from different groups have shown the association of c-Myc and cell proliferation 69 , Of considerable interest was the finding that S2TOTD showed a significantly lower antiproliferative effect when applied to normal human fibroblast cells MRC-5 Ideally, a c-Myc —targeted therapy should be active on cells with deregulated c-Myc and should not affect the majority of the normal cells in vivo.

This is of particular interest considering that the catalytic subunit of telomerase hTERT is transcriptionally regulated by c-Myc 27 , 78 and that activation or repression of c-Myc can alter hTERT activity in normal or tumor cells both in vitro and in vivo 22 , 28 , 79 — However, on the other hand, our finding that S2TOTD binds more potently to the c-Myc promoter sequence did not exclude a weaker binding to telomeric DNA with fold less efficiency.

Together with our discovery that S2TOTD exerted a direct inhibitory effect on TRAP activity in a cell-free system, this result suggests a possible direct inhibition of the telomerase enzyme by S2TOTD and could provide an explanation for the differences between the levels of c-Myc activity inhibition and the degree of hTERT activity reduction we observed in Fig.

Together, these data confirm that a functional c-Myc pathway, and not telomerase, is needed for S2TOTD to exert its antiproliferative effect. This observation counters the concern about the specificity of S2TOTD toward c-Myc and reveals that it is c-Myc inhibition rather than telomerase downregulation that is responsible for the proliferation arrest exerted by S2TOTD in our experiments.

The desired effect of telomerase inhibition would be to shorten telomeres to critical lengths, causing replicative senescence and preferably cell death. This finding was followed by apoptosis at day 35 in all cells treated.

In conclusion, we have shown the preferential recognition of the G-rich sequence in the c-Myc promoter over the telomere sequence by a novel small-molecule S2TOTD.

Mac reset sm@rt model:sv4 hours

Preparation, of compound To that ch1oroace ddehyde dinie;hylaweta; f fA:: The soiution is t-ie-Litral: Compound 43 2,00gs mmol i-S taken, 1i-i dsol zmt:. Lt; i3 1 i F1z, B ladeta 1.

The reaction is monitored lby TI-C. Scs l, ltion o f d;t;o: The reaction mixture wa. I’Example 24 the acrylarmdc: E H Step 2: Sviithrsis of hydrochloride salts 83, 84 and Protocol well pla e format: I, Dilute samp.

H, with am. Figure 4 shows die results oI’m FVli: The prev;pit,-Aod product was cooleki in ice and filte: A3i-ten-butul dicarbonate g, 0. I to 70T and stirred for 24 K. Aal the solvents were removed uiidez roduced pressure a-ac?

Syntheais of Michael ftddifion pr0diret The diamine gg,, 0. After the complote d: Synthesis of tiae hydrochio. N N, o HCI,: I g g, L moI, pur;: I 7, Found 4: L was added intv a solution of compoti.: C wrtd Mass spee:.

Alwx;3 arid DSC, L and [hc, or”atuc, aa-,,s: C, diluted with DCM, wa: Sum The residue was dried under 3i: Qs4 was added and sfi. I8 rnK 1fl, 4. EtNAt Tenninzal filtration was Pe..

Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described. The preparation of claim 1, wherein when R is not H, R is R a.

The preparation of claim 1, wherein when R is not H, R is R b. The preparation of claim 1, wherein when R is not H, R is R c. The preparation of claim 1, wherein when R is not H, R is R d. The preparation of claim 1, wherein when R is not H R is R e.

The preparation of claim 1, wherein n is 2. The preparation of claim 1, wherein n is 0. The preparation of claim 1, wherein X a and X b are C2 alkylene. The preparation of claim 1, wherein n is 0 and X b is ethylene or propylene.

The preparation of claim 1, wherein when R not H, R is. The preparation of claim 24, wherein Y is O or NR2. The preparation of claim 24, wherein m is 2. The preparation of claim 24 wherein Y is O or NR2 and m is 2.

The preparation of claim 24, wherein m is 1. The preparation of claim 1, wherein R1 for at least one occurrence is alkyl. The preparation of claim 1, wherein R1 for each occurrence is alkyl.

The preparation of claim 1, wherein R1 is alkyl and R2 is H. The preparation of claim 1, wherein R1 and R2 are alkyl. The preparation of claim 1, wherein R1 for at least one occurrence is alkenyl.

The preparation of claim 35, wherein Y is O. The preparation of claim 35, wherein Y is NH. The preparation of claim 35, wherein R1 is alkyl. The preparation of claim 38, wherein R1 is C alkyl.

The preparation of claim 39, wherein R1 is C12 alkyl. The preparation of claim 35, wherein n is 2. The preparation of claim 41, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene.

The preparation of claim 35, wherein m is 2. The preparation of claim 1, wherein n is 2 and R, when R is not H, is R a. The preparation of claim 44, wherein R1 is alkyl. The preparation of claim 45, wherein R1 is C alkyl.

The preparation of claim 46, wherein R1 is C12 alkyl. The preparation of claim 44, wherein Y is O. The preparation of claim 44, wherein Y is NH. The preparation of claim 44, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene.

The preparation of claim 44, wherein m is 2. The preparation of claim 52, wherein Y is O. The preparation of claim 52, wherein Y is NH. The preparation of claim 52, wherein R1 is alkyl. The preparation of claim 55, wherein R1 is C alkyl.

The preparation of claim 56, wherein R1 is C12 alkyl. The preparation of claim 58, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene.

The preparation of claim 52, wherein m is 2. The preparation of claim 61, wherein R1 is alkyl. The preparation of claim 62, wherein R1 is C alkyl. The preparation of claim 63, wherein R1 is C12 alkyl.

The preparation of claim 61, wherein Y is O. The preparation of claim 61, wherein Y is NH. The preparation of claim 61, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene.

The preparation of claim 61 , wherein m is 2. The preparation of claim 69, wherein Y is O. The preparation of claim 69, wherein Y is NH. The preparation of claim 69, wherein R1 is alkyl.

The preparation of claim 72, wherein R1 is C alkyl. The preparation of claim 73, wherein R1 is C12 alkyl. The preparation of claim 69, wherein n is 2. The preparation of claim 69, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene.

The preparation of claim 69, wherein m is 2. The preparation of claim 78, wherein R1 is alkyl. The preparation of claim 79, wherein R1 is C alkyl. The preparation of claim 80, wherein R1 is C12 alkyl.

The preparation of claim 78, wherein Y is O. The preparation of claim 78, wherein Y is NH. The preparation of claim 78, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene. The preparation of claim 78, wherein m is 2.

The preparation of claim 1, wherein n is 0 and X is propylene. The preparation of claim 86, wherein 1 R is H. The preparation of claim 86, wherein when R is not H, R is R a.

The preparation of claim 86, wherein R1 is alkyl. The preparation of claim 89, wherein R1 is C alkyl. The preparation of claim 90, wherein R1 is C12 alkyl. The preparation of claim 86, wherein Y is O.

The preparation of claim 86, wherein Y is NH. The preparation of claim 86, wherein m is 2. The preparation of claim 95, wherein Y is NH. The preparation of claim 98, wherein R is R a, for 5 occurrences.

The preparation of claim, wherein Y is NH. The preparation of claim 95, wherein the compound of formula I is an inorganic or organic salt thereof. The preparation of claim, wherein the compound of formula I is a hydrohalide salt thereof.

The preparation of claim, the compound of formula I is a hydrochloride salt thereof. The preparation of claim 1, comprising a hydrate of the compound of formula I. The preparation of claim 1, wherein the compound of formula I is salt of an organic acid.

The preparation of claim, wherein the salt is an acetate. The preparation of claim, wherein the salt is an formate. The preparation of claim 1, wherein R1 comprises an alkenyl moiety.

The preparation of claim, wherein R1 comprises a cis double bond. The preparation of claim 1, the preparation comprising a plurality of compounds of formula I. The preparation of claim, the preparation comprising a mixture of compounds of the formulas below: The preparation of claim, wherein formula I’ and I” and present in a ratio of from about 1: A method of making a compound of formula II, wherein each X a and X b, for each occurrence, is independently C alkylene; n is 0, 1, 2, 3, 4, or 5; and wherein each R is independently H or m is 2; Y is O, NR2, or S; R1 is alkyl or alkenyl; R2 is H or C alkyl or alkenyl; the method comprising reacting a compound of formula III with a compound of formula IV, in the presence of a promoter.

A method of making a compound of formula II, wherein each X a and X B, for each occurrence, is independently C alkylene: A method of making a compound of formula II, wherein each Xa and Xb, for each occurrence, is independently C alkylene; n is 0,1,2,3,4, or 5; and wherein each R is independently H or m is 2; Y is O, NR2, or S; R1 is alkyl or alkenyl; R2 is H or alkyl or a1kenyl; the method comprising reacting a compound of formula III with a compound of formula IV, wherein the reaction mixture comprises from about 0.

The method of claim, wherein the reaction mixture comprises from about 0. The method of claim, wherein the reaction mixture comprises about 1 molar equivalents of a compound of formula III, with from about 6 molar equivalents of a compound of formula IV.

The method of claim, wherein the reaction mixture comprises about 1 molar equivalents of a compound of formula III, with from about 5 molar equivalents of a compound of formula IV.

A method of making a compound of formula II, wherein each Xa and Xb, for each occurrence, is independently C alkylene; n is 0,1,2,3,4, or 5; and wherein each R is independently H or m is 2; Y is O, NR2 or S; R1 is alkyl or alkenyl; R2 is H or alkyl or alkenyl; the method comprising a two Step process of reacting a compound of formula III with a compound of formula IV, in the presence of boric acid and water wherein, the first step process involving the reaction mixture comprises from about 0.

A method of making a compound of formula Il, wherein each X a and X b, for each occurrence, is independently C alkylene; n is 0,1,2,3,4, or 5: The method of claim, wherein the chromatographic separation is using flash silica for separation of isomers.

The method of claim, wherein the chromatographic separation is gravity separation of isomers using silica gel. The method of claim, wherein the chromatographic separation is using moving bed chromatagraphy for separation of isomers.

The method of claim, wherein the chromatographic separation is using liquid chromatagraphy LC for separation of isomers. The method of claim, wherein the chromatographic separation using is normal phase HPLC for separation of isomers.

The method of claim, wherein the chromatographic separation is using reverse phase HPLC for separation of isomers. A method of making a compound of formula V or a pharmaccutically acceptable salt thereof, wherein each X a and X b, for each occurrence, is independently C alkylene; n is 0,1,2,3,4,or 5; and wherein each R is independently H or m is 1; Y is O, NR2, or S; R1 is alkyl or alkenyl; R2 is H or alkyl or alkenyl; the method compromising reacting a compound of formula III with a compound of formula VI, to provide a compound of formula V or a pharmaceutically acceptable salt thereof.

The method of claim, wherein the pharmaceutically acceptable salt thereof is a hydrochloride salt of the compound formula of the V. The compound of claim, wherein the compound is an inorganic salt thereof.

The compound of claim, wherein the compound is a hydrohalide salt thereof. The compound of claim, wherein the compound is a hydrochloride salt thereof. The compound of claim, wherein the compound is an organic salt thereof.

The compound of claim, wherein R1 and R2 are each independently C1-C3 alkyl. The compound of claim, wherein R1 is methyl. Aniolowski’s Malleus Monstrorum, p.

Trail of Cthulhu Adventures. Pagan Publishing, August Periodical role-playing game material. Baoht Z’uqqa-Mogg first appeared in this gaming supplement. Lumley expanded Sutton’s tale and gave his unnamed entity its name—Bugg-Shash—which effectively tied Sutton’s creation to the mythos.

Schwader’s “Fiesta For Our Lady” Webcomic version of this episode is available at http: Available online at http: The name is fictional, H. Lovecraft has not described it in the original story “The Temple”.

It is an original creation based on the Moon Ladder mentioned in the H. P Lovecraft novella “At the Mountains of Madness”. Lee’s “Genuine Article” Merritt ‘s Dwellers in the Mirage, a fantasy novel which involves many of H.

Though mentioned as a “Elder God” in the original story, the few details concerning Krang an evil mind and a hideous appearance according to description seem rather to qualify him as a “Great Old One”, since he has fallen in a death-like slumber, likely bound to mysterious astral conjunctions.

Aniolowski, Malleus Monstrorum, p. Lovecraft’s “Horror at Red Hook”. Lovecraft’s “The Hoard of Wizard-Beast” Daniel Harms believes that Pharol was invented by C. Moore, Henry Kuttner’s wife, since the being appears in many of her stories.

Stone of Death” Barlow ‘s “The Fidelity of Ghu” as rival or nemesis of Krang. Scans of the original comics are publicly viewable at http: Rollenspiel in der Welt des H. Lovecraft, in Jan Christoph Steines’ scenario “Jahrhundertsommer” i.

Lovecraft, which may in turn have itself influenced Merritt’s later story Dwellers in the Mirage. See The Moon Pool. Howard as a “demon-god”, very similar to Lovecraft’s Great Old Ones. Fultz; Jonathan Burns List of novels, short stories, essays, and other works Dream Cycle.

Lovecraft Encyclopedia Howard Phillips Lovecraft: Dreamer on the Nightside Lovecraft: The Guide to the Cinema of H. Lovecraft Historical Society Necronomicon Lovecraft: Fear of the Unknown documentary Kalem Club.

Retrieved from ” https: Cthulhu Mythos deities Fictional deities Lists of fictional deities. All articles with dead external links Articles with dead external links from August Articles with permanently dead external links All articles with unsourced statements Articles with unsourced statements from November CS1 maint: Views Read Edit View history.

This page was last edited on 3 April, at By using this site, you agree to the Terms of Use and Privacy Policy. A grey festering blob of infinite malevolence, described as the lesser brother of Tsathoggua or spawn of Cthulhu, born from his bile and tears.

A gigantic mysterious entity whose cult is perhaps coincident with that of Egyptian God Amun. Once dwelling in a gigantic palace known as Gz-eh near the Valley of the Kings, his dreaming force was able to shape reality.

Causing life to eventually flourish within the Nile Valley, over 3, years ago, before the stars ceased to be right, and the advancing desert entombed his titanic body beneath the sands. Priests of his cult have built up secret subterranean mausoleums to access the Great Old One’s body, and please the slumbering god by giving cattle as sacrificial victims.

A humanoid-torso with tentacles instead of limbs, and a short neck ending in a toothless, featureless mouth. A giant spider with a human – like face. Daughter of both Yig and the Outer Goddess Yidhra, appearing as a gigantic octopus-like horror with serpentine eyes, and detachable tentacles, which may move independently.

She dwells within the cavern of a deep canyon somewhere in Texas. A tall, shadowy humanoid figure with yellow glowing eyes, and strange protrusions like the branches of dead trees. She is a servant of Shub-Niggurath.

A huge, flying scorpion with an ant – like head. Not described, possibly a humanoid crustacean or a gigantic crab. Appears as a black slimy mass covered in eyes and mouths, much like a Shoggoth.

Appears as a gigantic multicolored toad with one eye, a proboscis, crab – like claws, and tentacles below the mouth. A vampiric elephant – like humanoid, with a mouth on the end of its trunk.

Serpent Skirted One [27]. Appears as a gigantic reptilian humanoid with two facing snakes in place of an actual head, as depicted in the Coatlicue statue. She was the former mate of Yig, revered in K’n-yan along with her consort.

A marine tentacled horror made of fish, whale, and octopus – like features. Master of the Runes, Bloody Crooked One [31]. Not described, but likely something gigantic and serpent or worm – like.

Half – sister of Cthulhu, which spawned the Star-Spawn of Cthulhu. A massive hybrid of human, octopus, and dragon. He is usually depicted as being hundreds of meters tall, with webbed arms, tentacles, and a pair of rudimentary wings on his back.

Appears as a huge winged octopus – like creature with six eyes. Youngest of Cthulhu and Idh-yaa’s progeny. Appears as a gigantic black mass of tentacles, with a single green eye at the center.

A serpentine likely Tremors – like earth-shaking horror dwelling in the subsoil of Memphis, US. The Dweller in the Gulf. Appears as a huge, eyeless, black, soft-shelled tortoise with a triangular head, two whip-like tails, and suckers on the end of each tail.

A jewel-facetted, semi-crystalline geode with mineral tentacles. A gigantic saurian creature similar to Bokrug, but terrestrial, and endowed with a mane of tentacles. A ravenous plant-god who arrived from Xiclotl to Earth, awed by the Insects from Shaggai.

He appears as a white orb hiding an enormous magenta excrescence, like an orchid or a lamprey – like mouth, with emerald tentacles, tipped with hands emerging from within the hideous mass.

Appears as a huge, pallid, gelatinous oval with a myriad of legs and multiple eyes. Lord of the Volcano, Thoa [35]. Appears as a colossal horror with multifarious appendages, and Gorgon – like powers.

A cosmic-entity manifesting as a gigantic, spongy, and fleshy mass covered in a myriad of both eyes and spines. He is said to be the nemesis of the Outer God Uvhash, usually summoned to contrast this deity.

Appears as a giant three-eyed slug with metallic spines, and tiny pyramid-like feet underneath. Usually manifests through a Dionysian sculpture, but its true form is that of a gigantic wattled slug – thing.

Appears as a colossal pillar of amorphous alien flesh, with a cyclopean head. It drags up the continent it is summoned in, and causes the entire world to suddenly cave-in on itself. A vaporous red entity haunting the rainforest of Central Africa.

It has the power to turn humans into zombie – like servants, the Tree-Men of M’bwa. A gigantic entity dwelling in some reverse dimension, resembling a huge bullet with a long proboscis. Appears as a gigantic, black, toad – like creature with an impossibly malevolent glare, or a tentacled, scaled, bat-winged entity.

An entity cut in ten pieces by Yig during a time of great battle one of these pieces is an alabaster dish found in Egypt, dated back 1, BC. It resembles and has a similar domain as the Greek god Bacchus.

A sentient plant – like entity dwelling within a series of subterranean caverns, where it is always served by mutant rabbit-like worshipers. A monstrous bird – like fiend with sharp teeth, dwelling beneath Antarctica, vaguely resembling an extinct pterosaur.

A destructive entity manifesting as a ravenous metallic vortex. He seems to be another half-brother of Cthulhu, like Hastur, and related to the slug-like Glaaki as well. He has also been called a “son of Yog-Sothoth “.

Whether these titles are literal or conceal some dark truth about the Destroyer, none can ascertain. He dwells somewhere in the Pleiades stellar region, and when summoned, he brings devastation.

A shadowy incorporeal entity dwelling in the Dreamlands. A great shadow thing, with two glaring red eyes, able to transform the skull of its victims into green glowing stones carved with strange symbols.

A tentacled amoebic horror with multiple eyes, orifices, and a dangling gland forming a hideous face. His true form is unknown, but usually manifests either as a polypous, ravenous floating mass endowed with tentacles, drills, and suckers, or more frequently, as the King in Yellow, a humanoid being wearing tattered, yellow clothes and a mask hiding the face.

He is said to be Cthulhu ‘s half – brother. He is said to be of the air element opposed to Cthulhu’s water element. A towering greenish trunk with a “crown” of tentacles, a row of multiple eyes, and a series of additional lateral grasping appendages.

Lesser brother of Cthulhu, manifesting as a gigantic mouth surrounded by countless tentacles, similar to a titanic sea anemone. Has a spheroid body, elongated arms, short legs, and a pendulum – like head dangling underneath.

He is the brother of Ghisguth, and uncle of Tsathoggua. A gigantic, pale, worm – like horror dwelling beneath the crust of the star Xoth. She has been Cthulhu ‘s first bride, and with him spawned three sons – Ghatanothoa, Ythogtha, and Zoth-Ommog – and a younger daughter, Cthylla.

A levitating, sinuous glowing creature. A cat – like deity, similar to Bastet, but vicious and malignant. Her sister is the sylvan Lythalia. A gigantic, corpse-like human, with webbed feet and glowing red eyes.

A crustacean – like, tentacled, half-amorphous marine horror which serves Cthulhu, dwelling in the depths of the Bay of Rhiiklu, somewhere within the eastern coast of the United States. The Ravenous One [40].

Likely a gigantic larva – like horror, dwelling in the nebulous realm of K’gil’mnon, along with the Gharoides, its parasitic insectoid servants. Kag’Naru of the Air [41]. Mentioned in the American comic book Challengers of the Unknown as the sister of M’Nagalah.

Acknowledgments We thank Dr. Received June 29, Revision received October 30, Accepted November 13, Current treatment of medulloblastoma: Semin Oncol ; J Neurosurg ; Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors.

Oncologist ; 8: Am J Surg Pathol ; Clin Cancer Res ; 8: Pediatr Neurosurg ; J Clin Oncol ; Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus.

J Am Chem Soc ; Oncogene ; Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res ; Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin SOT, against human leukemia cells: Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells.

Eur J Cancer ; Synthesis of a potent G-quadruplex-binding macrocyclic heptaoxazole. Chembiochem ; Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex.

Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Chromatin structure and protein binding in the putative regulatory region of the c-myc gene in Burkitt lymphoma.

Cell ; Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science ; The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.

Mol Cancer Ther ; 1: Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element. The role of c-myc in cellular growth control. Nature ; Genes Dev ; Nat Genet ; Reversible tumorigenesis by MYC in hematopoietic lineages.

Mol Cell ; 4: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nat Med ; 7: Arnold I, Watt FM. Curr Biol ; Targeting Myc in pediatric malignancies of the central and peripheral nervous system.

Curr Cancer Drug Targets ; 9: Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. N-myc and c-myc oncogenes amplification in medulloblastomas.

Evidence of particularly aggressive behavior of a tumor with c-myc amplification. Tumori ; C-myc expression in medulloblastoma and its prognostic value. Int J Cancer ; Clin Cancer Res ; 7: Expression of the c-Myc protein in childhood medulloblastoma.

J Pediatr Hematol Oncol ; Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res ; A fluorescence in situ hybridization study on paraffin sections from the Children’s Oncology Group.

Arch Pathol Lab Med ; Brain Pathol ; Oncogene amplification in medulloblastoma: Pathology ; Histopathological and molecular prognostic markers in medulloblastoma: J Neuropathol Exp Neurol ; Macrocyclic hexaoxazoles as sequence – and mode-selective G-quadruplex binders.

Angew Chem Int Ed Engl ; Telomere maintenance in childhood primitive neuroectodermal brain tumors. Neuro-oncol ; 6: Quantitative mRNA expression analysis of neurotrophin-receptor TrkC and oncogene c-MYC from formalin-fixed, paraffin-embedded primitive neuroectodermal tumor samples.

Neuropathology ; Anti-proliferative activity of the quassinoid NBT in childhood medulloblastoma cells. BMC Cancer ; 7: J Virol ; Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands.

TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors.

Klin Padiatr ; Stabilization of the c-myc gene promoter quadruplex by specific ligands’ inhibitors of telomerase.

The preparation of claim 1, wherein R1 is alkyl and R2 is H. The preparation of claim 1, wherein R1 and R2 are alkyl. The preparation of claim 1, wherein R1 for at least one occurrence is alkenyl.

The preparation of claim 35, wherein Y is O. The preparation of claim 35, wherein Y is NH. The preparation of claim 35, wherein R1 is alkyl. The preparation of claim 38, wherein R1 is C alkyl.

The preparation of claim 39, wherein R1 is C12 alkyl. The preparation of claim 35, wherein n is 2. The preparation of claim 41, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene.

The preparation of claim 35, wherein m is 2. The preparation of claim 1, wherein n is 2 and R, when R is not H, is R a. The preparation of claim 44, wherein R1 is alkyl. The preparation of claim 45, wherein R1 is C alkyl.

The preparation of claim 46, wherein R1 is C12 alkyl. The preparation of claim 44, wherein Y is O. The preparation of claim 44, wherein Y is NH. The preparation of claim 44, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene.

The preparation of claim 44, wherein m is 2. The preparation of claim 52, wherein Y is O. The preparation of claim 52, wherein Y is NH. The preparation of claim 52, wherein R1 is alkyl.

The preparation of claim 55, wherein R1 is C alkyl. The preparation of claim 56, wherein R1 is C12 alkyl. The preparation of claim 58, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene.

The preparation of claim 52, wherein m is 2. The preparation of claim 61, wherein R1 is alkyl. The preparation of claim 62, wherein R1 is C alkyl. The preparation of claim 63, wherein R1 is C12 alkyl.

The preparation of claim 61, wherein Y is O. The preparation of claim 61, wherein Y is NH. The preparation of claim 61, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene. The preparation of claim 61 , wherein m is 2.

The preparation of claim 69, wherein Y is O. The preparation of claim 69, wherein Y is NH. The preparation of claim 69, wherein R1 is alkyl. The preparation of claim 72, wherein R1 is C alkyl.

The preparation of claim 73, wherein R1 is C12 alkyl. The preparation of claim 69, wherein n is 2. The preparation of claim 69, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene.

The preparation of claim 69, wherein m is 2. The preparation of claim 78, wherein R1 is alkyl. The preparation of claim 79, wherein R1 is C alkyl. The preparation of claim 80, wherein R1 is C12 alkyl.

The preparation of claim 78, wherein Y is O. The preparation of claim 78, wherein Y is NH. The preparation of claim 78, wherein X a, for each occurrence is C2 alkylene and X b is C2 alkylene. The preparation of claim 78, wherein m is 2.

The preparation of claim 1, wherein n is 0 and X is propylene. The preparation of claim 86, wherein 1 R is H. The preparation of claim 86, wherein when R is not H, R is R a.

The preparation of claim 86, wherein R1 is alkyl. The preparation of claim 89, wherein R1 is C alkyl. The preparation of claim 90, wherein R1 is C12 alkyl. The preparation of claim 86, wherein Y is O.

The preparation of claim 86, wherein Y is NH. The preparation of claim 86, wherein m is 2. The preparation of claim 95, wherein Y is NH. The preparation of claim 98, wherein R is R a, for 5 occurrences.

The preparation of claim, wherein Y is NH. The preparation of claim 95, wherein the compound of formula I is an inorganic or organic salt thereof. The preparation of claim, wherein the compound of formula I is a hydrohalide salt thereof.

The preparation of claim, the compound of formula I is a hydrochloride salt thereof. The preparation of claim 1, comprising a hydrate of the compound of formula I. The preparation of claim 1, wherein the compound of formula I is salt of an organic acid.

The preparation of claim, wherein the salt is an acetate. The preparation of claim, wherein the salt is an formate. The preparation of claim 1, wherein R1 comprises an alkenyl moiety.

The preparation of claim, wherein R1 comprises a cis double bond. The preparation of claim 1, the preparation comprising a plurality of compounds of formula I. The preparation of claim, the preparation comprising a mixture of compounds of the formulas below: The preparation of claim, wherein formula I’ and I” and present in a ratio of from about 1: A method of making a compound of formula II, wherein each X a and X b, for each occurrence, is independently C alkylene; n is 0, 1, 2, 3, 4, or 5; and wherein each R is independently H or m is 2; Y is O, NR2, or S; R1 is alkyl or alkenyl; R2 is H or C alkyl or alkenyl; the method comprising reacting a compound of formula III with a compound of formula IV, in the presence of a promoter.

A method of making a compound of formula II, wherein each X a and X B, for each occurrence, is independently C alkylene: A method of making a compound of formula II, wherein each Xa and Xb, for each occurrence, is independently C alkylene; n is 0,1,2,3,4, or 5; and wherein each R is independently H or m is 2; Y is O, NR2, or S; R1 is alkyl or alkenyl; R2 is H or alkyl or a1kenyl; the method comprising reacting a compound of formula III with a compound of formula IV, wherein the reaction mixture comprises from about 0.

The method of claim, wherein the reaction mixture comprises from about 0. The method of claim, wherein the reaction mixture comprises about 1 molar equivalents of a compound of formula III, with from about 6 molar equivalents of a compound of formula IV.

The method of claim, wherein the reaction mixture comprises about 1 molar equivalents of a compound of formula III, with from about 5 molar equivalents of a compound of formula IV. A method of making a compound of formula II, wherein each Xa and Xb, for each occurrence, is independently C alkylene; n is 0,1,2,3,4, or 5; and wherein each R is independently H or m is 2; Y is O, NR2 or S; R1 is alkyl or alkenyl; R2 is H or alkyl or alkenyl; the method comprising a two Step process of reacting a compound of formula III with a compound of formula IV, in the presence of boric acid and water wherein, the first step process involving the reaction mixture comprises from about 0.

A method of making a compound of formula Il, wherein each X a and X b, for each occurrence, is independently C alkylene; n is 0,1,2,3,4, or 5: The method of claim, wherein the chromatographic separation is using flash silica for separation of isomers.

The method of claim, wherein the chromatographic separation is gravity separation of isomers using silica gel. The method of claim, wherein the chromatographic separation is using moving bed chromatagraphy for separation of isomers.

The method of claim, wherein the chromatographic separation is using liquid chromatagraphy LC for separation of isomers. The method of claim, wherein the chromatographic separation using is normal phase HPLC for separation of isomers.

The method of claim, wherein the chromatographic separation is using reverse phase HPLC for separation of isomers. A method of making a compound of formula V or a pharmaccutically acceptable salt thereof, wherein each X a and X b, for each occurrence, is independently C alkylene; n is 0,1,2,3,4,or 5; and wherein each R is independently H or m is 1; Y is O, NR2, or S; R1 is alkyl or alkenyl; R2 is H or alkyl or alkenyl; the method compromising reacting a compound of formula III with a compound of formula VI, to provide a compound of formula V or a pharmaceutically acceptable salt thereof.

The method of claim, wherein the pharmaceutically acceptable salt thereof is a hydrochloride salt of the compound formula of the V. The compound of claim, wherein the compound is an inorganic salt thereof.

The compound of claim, wherein the compound is a hydrohalide salt thereof. The compound of claim, wherein the compound is a hydrochloride salt thereof. The compound of claim, wherein the compound is an organic salt thereof.

The compound of claim, wherein R1 and R2 are each independently C1-C3 alkyl. The compound of claim, wherein R1 is methyl. The compound of claim, wherein R2 is methyl. The compound of claim, wherein R1 and R3 are both methyl.

The compound of claim, wherein R1 is H, methyl, ethyl, isopropyl, or 2-hydroxyethyl. The compound of c1aim, wherein R2 is H. The compound of claim, wherein R2 is ethyl. The compound of claim, wherein R2 is propyl.

The compound of claim, wherein R2 is isopropyl. The compound of claim, wherein R2 is H, methyl, ethyl, propyl, or isopropyl. The compound of claim, wherein R1 is H, methyl, ethyl, isopropyl, or 2-hydroxyethyl and R2 is H, methyl, ethyl, propyl, or isopropyl.

The compound of claim, wherein m is 1. The compound of claim, wherein n is 1. The compound of claim, wherein both m and n are 1. The compound of claim, wherein L1 is S-S-. The compound of claim, wherein L2 is S-S-.

The compound of claim, wherein both L1 and L2 are S-S-. The compound of claim, wherein L1-R3 and L2-R4 are taken together to form an acetal, a ketal, or an orthoester. The compound of claim, wherein each R3 and R4 are independently alkyl.

The compound of claim, wherein both R3 and R4 are C6-C28 alkyl. The compound of claim, wherein R3 is alkyl. The compound of claim, wherein R4 is alkyl. The compound of claim, wherein R3 is alkenyl.

The compound of claim, wherein R4 is alkenyl. The compound of claim, wherein each R3 and R4 are independently alkenyl. The compound of claim, wherein each R3 and R4 are independently C6-C30 alkenyl.

The compound of claim, wherein each R3 and R4 are the same alkenyl moiety. The compound of claim, wherein each R3 and R4 includes two double bond moieties. The compound of claim, wherein at least one of the double bonds have a Z configuration.

The compound of claim, wherein both of the double bonds have a Z configuration. The compound of claim, wherein at least one of R3 and R4 is provided in formula II below wherein x is an integer from 1 to 8; and y is an integer from The compound of claim, wherein both of R3 and R4 are of the formula II.

The compound of claim, wherein at least one of the double bonds have an E configuration. The compound of claim, wherein both of the double bonds have an E configuration.

The compound of claim, wherein at least one of R1 and R2 is provided in formula III below wherein x is an integer from 1 to 8; and y is an integer from The compound of claim, wherein each R1 and R2 includes three double bond moieties.

The compound of claim, wherein at least two of the double bonds have a Z configuration. The compound of claim, wherein all three of the double bonds have a Z configuration.

The compound of claim, wherein at least one of R1 and R2 is provided in formula IV below wherein x is an integer from 1 to 8; and y is an integer from 1 The compound of claim, wherein both of R1 and R2 are as provided in formula IV.

The compound of claim, wherein at least two of the double bonds have an E configuration. The compound of claim, wherein all three of the double bonds have an E configuration.

The compound of claim, wherein at least one of R1 and R2 is provided in formula IV below formula V wherein x is an integer from 1 to 8; and y is an integer from The compound of claim, wherein both of R1 and R2 are as provided in formula V.

A preparation comprising a compound of formula X. The method of claim, wherein the coupling agent is a carbodiimide. The method of claim, wherein the coupling reagent is EDCI.

A method of forming an association complex comprising contacting a lipid preparation of claim 1 or claim with a therapeutic agent in the presence of a buffer, wherein said buffer: An association complex made by the method of claim The method of claim, wherein the particle has a diameter of less than about 50 uM.

A method of forming an association complex comprising contacting a lipid preparation of claim 1 or claim with a therapeutic agent in the presence of a buffer, wherein said buffer has a concentration from about to about mM.

An association complex comprising a preparation of claim 1 or claim and a nucleic acid. The association complex of claim, further comprising a PEGylated lipid. The association complex of claim, further comprising a structural moiety.

The association complex of claim, wherein the structural moiety is cholesterol. The association complex of claim, wherein said nucleic acid is an siRNA. The association complex of claim, wherein said nucleic acid is an siRNA which has been modified to resist degradation.

The association complex of claim, wherein said nucleic acid is an siRNA which has been modified by modification of the polysaccharide backbone. The association complex of claim, wherein the siRNA targets a gene or genes of interest.

The association complex of claim, wherein the gene or genes of interest is an endogeneously expressed gene in liver. The association complex of claim, wherein the gene of interst is apoB.

The association complex of claim, wherein the gene of interest is FVII. The association complex of claim, wherein the gene of interest is PCSK9. The association complex of claim, wherein the gene of interest is VEGF.

The association complex of claim, wherein the gene of interest is KSP eg5. The association complex of claim, wherein the gene of interest is hepcidin. The association complex of claim, wherein the gene of interest is HCV.

The association complex of claim, wherein said nucleic acid is a single stranded nucleic acid or derivatives thereof. The association complex of claim, wherein the nucleic acid is an antisense nucleic acid.

The association complex of claim, wherein the nucleic acid is a microRNA. The association complex of claim, wherein the nucleic acid is an antisense oligonucleotide of microRNA antagomir.

The association complex of claim, wherein the nucleic acid is against microRNA – The association complex of claim, wherein the nucleic acid is against microRNA The association complex of claim, further comprising a structural moiety and a PEGylated lipid, wherein the ratio, by weight, of preparation of claim 1 or claim, structural moiety, PEGylated lipid, and a nucleic acid, is The association complexof claim, wherein the ratio is The association complex of claim, wherein the ratio is The association complex of claim, wherein the average liposome diameter is between 10 nm and nm.

The association complex of claim wherein the average association complex diameter is between 30 and nm. The association complex of claim, wherein the average association complex diameter is between 50 and nm.

A pharmaceutically acceptable composition comprising the preparation of claim 1 or claim A pharmaceutically acceptable composition comprising the association complex of claim A method of treating a mammal comprising administering to said mammal a therapeutic amount of an association complex of claim A preparation of claim 1, wherein the preparation comprises one or a mixture of the formula below, wherein R is not H unless specified in the formula below.

The preparation of claim 1, wherein the preparation consists essentially of one or a mixture of the formula below. The preparation of claim, wherein each R is. The preparation of claim wherein each R is.

The preparation of claims or, wherein R1 is CC18 alkyl e. C12 alkyl, or CC30 alkenyl. The preparation of claim wherein R is. The preparation of claim, wherein R1 isCC18 alkyl.

The preparation of claim, wherein R1 is C12 alkyl and R2 is H. The preparation of claim, wherein formula I is provided below, wherein R is no H unless specifically recited: The preparation of claim, wherein formula I is provided below, wherein R is not H unless specifically recited: The preparation of claim 1, wherein formula I is provided below, wherein R is not H unless specifically recited.

The preparation of claim, wherein R is. A method of forming an association complex comprising a plurality of lipid moieties and a therapeutic agent, the method comprising: The method of claim, wherein the plurality of lipid moieties comprises a cationic lipid.

The method of claim, wherein the cationic lipid is a lipid of claim 1 or claim The method of claim, wherein the cationic lipid is a lipid of one of the following or a mixture thereof: The method of claim, wherein the plurality of lipid moieties comprises a PEG-lipid.

The method of claim, wherein the PEG-lipid has the following structure: The method of claim, wherein the PEG-lipid is. The method of claim, wherein the plurality of lipid moieties comprises a structural lipid.

The method of claim, wherein the structural lipid is cholesterol. The method of claim, further comprising extruding the lipid containing particles. The method of claim, wherein the lipid containing particles are extruded prior to addition of the therapeutic agent.

The method of claim, wherein the therapeutic agent is a nucleic acid. The method of claim, wherein the nucleic acid is an siRNA. The method of claim, wherein said nucleic acid is an siRNA which has been modified to resist degradation.

The method of claim, wherein said nucleic acid is an siRNA which has been modified by modification of the polysaccharide backbone. The method of claim, siRNA is conjugated to a Lipophilic moiety.

The method of claim, wherein said the siRNA targets a gene or genes of interest. The method of claim, wherein the gene or genes of is an endogeneously expressed gene in liver.

The method of claim, wherein the gene of interest is apoB. The method of claim, wherein the gene of is FVII. The method of claim, wherein the gene of is PCSK9. The method of claim, wherein the gene of is VEGF.

The method of claim, wherein the gene of is KSP eg5. The method of claim, wherein the gene of is hepcidin. The method of claim, wherein the gene of is HCV.

The method of claim, wherein said nucleic acid is a single stranded nucleic acid or derivatives thereof. The method of claim, wherein the nucleic acid is an antisense nucleic acid.

The method of claim, wherein the nucleic acid is a microRNA. The method of claim, wherein the nucleic acid is an antimicroRNA antagomir. The method of claim, wherein the association complex comprises a cationic lipid, a structural lipid, a PEG-lipid and a nucleic acid.

The method of claim, wherein the molar ratio of the cationic lipid, structural lipid, PEG-lipid and nucleic acid is The method of claim, wherein the molar ratio of the cationic lipid, structural lipid, PEG-lipid and nucleic acid is about However the exiled deity is not dead, but just sleeping, and one day he will rise again from his abyss manifesting himself as a blue, 6-meters tall, cyclops – like monstrosity, with the bulk of his body covered entirely in crawling worms.

A goat-like fiendish horror with bat wings and multiple horns, mentioned as the brother of Shub-Niggurath. Olkoth God of the Celestial Arcs [11] appears as a demoniacal god-like entity able to reincarnate in human bodies if the stars are right sort of a “Cthulhian” Antichrist.

Shabbith-Ka appears as a shapeless, roughly man-sized purplish aura, spitting and crackling with powerful electrical arcs. A sense of power, malignancy, and intelligence accompanies it and persons able to gaze at its form long enough can see a rudimentary face or faces within the glowing mass.

The Star Mother appears as a chunk of yellow-green stone about the size of an infant. Its shape suggests a plump, huge-breasted, faceless female figure. From it extend dozens of pencil-thin root-like strands.

It is one of the Larvae of the Other Gods and has no cult, although served by zombie slaves. Suc’Naath is one of the mindless gods which twist and dance in the court of Azathoth. It appears as a formless spinning hurricane – like thing with strings of violet and golden colors across its shape, constantly emitting, sickening, smacking, and screeching noises, while showing pain-stricken faces appearing on its body.

Suc’Naath’s essence is currently divided into three parts, one in a comet called Aiin, the other in some sort of statue located somewhere in the World, while the third has been genetically passed on for aeons through prehuman, and now human races of earth, mostly in the middle east.

If these three parts are ever to be combine, Suc’Naath will be freed. This entity is served by a small middle-eastern cult known as the Golden Hands of Suc’Naath, who collect deranged intellectuals and trained assassins, who wish to set Suc’Naath free they may have connections to the old Hashashin cult as well.

It has no shape, but manifests as haunting music. Tulzscha appears as a blazing green ball of flame, dancing with its Lesser Outer Gods at the court of Azathoth. Called to our world, it assumes a gaseous form, penetrates the planet to the core, then erupts from below as a pillar of flame.

It cannot move from where it emerges. Uvhash The Blood-Mad God of the Void appears as a colossal, vampiric, red mass of both tentacles and eyes. It dwells within the realm of Rhylkos, which matches with the red planet Mars, and whoever summons Uvhash witnesses an atrocious death.

He has affinities with the star vampires, and is rumored to have been one of mad emperor Caligula ‘s eldritch sponsors as well. There is some affinity with the Great Old One Hastur [13].

She spawned the Great Old One Zstylzhemgni by fission. A gigantic, bat-winged humanoid with detached eyes, wearing a green robe. This horrible deity sees all time and space as it slowly rotates in the centre of its clearing within the Jungle of Kled, in Earth’s Dreamlands.

Beneath its billowing cloak are a multitude of nightgaunts, suckling and clutching at her breasts. Yidhra The Dream Witch or Yee-Tho-Rah [17] usually appears as a youthful, attractive, earthly female, though her shape may vary.

Yidhra has been on Earth since the first microorganisms appeared and is immortal. To survive in a changing environment, she gained the ability to take on the characteristics of any creature that she devoured.

Over time, Yidhra split herself into different aspects, though each part shares her consciousness. Members of Yidhra’s cult can gain immortality by merging with her, though they become somewhat like Yidhra as a consequence.

Those who serve her are also promised plentiful harvests and healthy livestock. She usually conceals her true form behind a powerful illusion, appearing as a comely young woman; only favored members of her cult can see her as she actually is.

He waits in his home dimension in Pherkard, until he is summoned to Earth. The reptilian burrowing folk, the Rhygntu, are known to worship this malignant deity. An ongoing theme in Lovecraft’s work is the complete irrelevance of mankind in the face of the cosmic horrors that apparently exist in the universe, with Lovecraft constantly referring to the “Great Old Ones”: Lovecraft named several of these deities, including Cthulhu, Ghatanothoa, and Yig.

With a few exceptions, Cthulhu, Ghatanothoa, et al. Though worshipped by deranged human and inhuman cults, these beings are generally imprisoned or restricted in their ability to interact with most people beneath the sea, inside the Earth, in other dimensions, and so on, at least until the hapless protagonist is unwittingly exposed to them.

Lovecraft visited this premise in many of his stories, notably his short story, The Call of Cthulhu, with reference to the eponymous creature. However, it was Derleth who applied the notion to all of the Great Old Ones.

The majority of these have physical forms that the human mind is incapable of processing; simply viewing them renders the viewer incurably insane. Miivls and Vn’Vulot, are said to have fought each other in southern Gondwanaland during the Cretaceous period, whereas Rynvyk, regarded as one of the mates of Cthulhu ‘s sister Kassogtha, likely matches with Cthulhu itself or a similar entity.

Kassogtha would have sired Rynvyk three sons one named Ult and Rynvyk himself currently rests in a crimson pool in the Hall of Tyryar likely another name or dimension of R’lyeh, whose portal is located somewhere in Norway.

The Great Ones are the “weak gods of earth” that reign in the Dreamlands. They are protected by Nyarlathotep. In post-Lovecraft stories, the Elder Gods oppose the likes of Cthulhu and his ilk.

Derleth attempted to retroactively group the benevolent deity Nodens in this category who acts as deus ex machina for the protagonists in both The Dream-Quest of Unknown Kadath and ” The Strange High House in the Mist “.

Pulver mentions in his Nightmare’s Disciple a series of original Elder Gods, though lacking of any description about their true form. Eppirfon was originally Cthulhu ‘s second bride who bore him a son, T’ith, now dead, murdered by Cthulhu himself.

A creation of Brian Lumley, Kthanid looks the same as Cthulhu except for eye colour. Although its expression is bright and blinding, no one feels its heat. No one can look at Orryx more than a few seconds; after the first glance, the eyes of anyone who looks become sore and watery.

It is symbolized by a seven-pointed star symbol, which is his own Seal. Nodens “Lord of the Great Abyss” appears as a human male riding a huge seashell pulled by legendary beasts. Another Brian Lumley deity.

Yaggdytha “The Incandescent One” is twin brother of Vorvadoss, manifesting as a great, amorphous, incandescent ball of cyan living energy, spreading itself into a web of giant talons of light.

From Wikipedia, the free encyclopedia. Cthulhu Mythos reference codes and bibliography. Old One in fiction. List of Great Old Ones. Lovecraft and the Cthulhu Mythos”, Crypt of Cthulhu 35 , p. McKinnon and Dylan K.

Aniolowski’s Malleus Monstrorum, p. Trail of Cthulhu Adventures. Pagan Publishing, August Periodical role-playing game material. Baoht Z’uqqa-Mogg first appeared in this gaming supplement.

Lumley expanded Sutton’s tale and gave his unnamed entity its name—Bugg-Shash—which effectively tied Sutton’s creation to the mythos. Schwader’s “Fiesta For Our Lady” Webcomic version of this episode is available at http: Available online at http: The name is fictional, H.

Lovecraft has not described it in the original story “The Temple”. It is an original creation based on the Moon Ladder mentioned in the H. P Lovecraft novella “At the Mountains of Madness”.

Lee’s “Genuine Article” Merritt ‘s Dwellers in the Mirage, a fantasy novel which involves many of H. Though mentioned as a “Elder God” in the original story, the few details concerning Krang an evil mind and a hideous appearance according to description seem rather to qualify him as a “Great Old One”, since he has fallen in a death-like slumber, likely bound to mysterious astral conjunctions.

Aniolowski, Malleus Monstrorum, p. Lovecraft’s “Horror at Red Hook”. Lovecraft’s “The Hoard of Wizard-Beast” Daniel Harms believes that Pharol was invented by C.

Moore, Henry Kuttner’s wife, since the being appears in many of her stories. Stone of Death” Barlow ‘s “The Fidelity of Ghu” as rival or nemesis of Krang. Scans of the original comics are publicly viewable at http: Rollenspiel in der Welt des H.

Lovecraft, in Jan Christoph Steines’ scenario “Jahrhundertsommer” i. Lovecraft, which may in turn have itself influenced Merritt’s later story Dwellers in the Mirage. See The Moon Pool.

Howard as a “demon-god”, very similar to Lovecraft’s Great Old Ones. Fultz; Jonathan Burns List of novels, short stories, essays, and other works Dream Cycle. Lovecraft Encyclopedia Howard Phillips Lovecraft: Dreamer on the Nightside Lovecraft: The Guide to the Cinema of H.

Lovecraft Historical Society Necronomicon Lovecraft: Fear of the Unknown documentary Kalem Club. Retrieved from ” https: Cthulhu Mythos deities Fictional deities Lists of fictional deities. All articles with dead external links Articles with dead external links from August Articles with permanently dead external links All articles with unsourced statements Articles with unsourced statements from November CS1 maint: Views Read Edit View history.

This page was last edited on 3 April, at By using this site, you agree to the Terms of Use and Privacy Policy. A grey festering blob of infinite malevolence, described as the lesser brother of Tsathoggua or spawn of Cthulhu, born from his bile and tears.

A gigantic mysterious entity whose cult is perhaps coincident with that of Egyptian God Amun. Once dwelling in a gigantic palace known as Gz-eh near the Valley of the Kings, his dreaming force was able to shape reality.

Causing life to eventually flourish within the Nile Valley, over 3, years ago, before the stars ceased to be right, and the advancing desert entombed his titanic body beneath the sands. Priests of his cult have built up secret subterranean mausoleums to access the Great Old One’s body, and please the slumbering god by giving cattle as sacrificial victims.

A humanoid-torso with tentacles instead of limbs, and a short neck ending in a toothless, featureless mouth. A giant spider with a human – like face. Daughter of both Yig and the Outer Goddess Yidhra, appearing as a gigantic octopus-like horror with serpentine eyes, and detachable tentacles, which may move independently.

She dwells within the cavern of a deep canyon somewhere in Texas. A tall, shadowy humanoid figure with yellow glowing eyes, and strange protrusions like the branches of dead trees. She is a servant of Shub-Niggurath.

A huge, flying scorpion with an ant – like head. Not described, possibly a humanoid crustacean or a gigantic crab. Appears as a black slimy mass covered in eyes and mouths, much like a Shoggoth. Appears as a gigantic multicolored toad with one eye, a proboscis, crab – like claws, and tentacles below the mouth.

A vampiric elephant – like humanoid, with a mouth on the end of its trunk. Serpent Skirted One [27]. Appears as a gigantic reptilian humanoid with two facing snakes in place of an actual head, as depicted in the Coatlicue statue.

She was the former mate of Yig, revered in K’n-yan along with her consort. A marine tentacled horror made of fish, whale, and octopus – like features. Master of the Runes, Bloody Crooked One [31].

Not described, but likely something gigantic and serpent or worm – like. Half – sister of Cthulhu, which spawned the Star-Spawn of Cthulhu. A massive hybrid of human, octopus, and dragon. He is usually depicted as being hundreds of meters tall, with webbed arms, tentacles, and a pair of rudimentary wings on his back.

Appears as a huge winged octopus – like creature with six eyes. Youngest of Cthulhu and Idh-yaa’s progeny. Appears as a gigantic black mass of tentacles, with a single green eye at the center.

A serpentine likely Tremors – like earth-shaking horror dwelling in the subsoil of Memphis, US. The Dweller in the Gulf. Appears as a huge, eyeless, black, soft-shelled tortoise with a triangular head, two whip-like tails, and suckers on the end of each tail.

A jewel-facetted, semi-crystalline geode with mineral tentacles. A gigantic saurian creature similar to Bokrug, but terrestrial, and endowed with a mane of tentacles. A ravenous plant-god who arrived from Xiclotl to Earth, awed by the Insects from Shaggai.

He appears as a white orb hiding an enormous magenta excrescence, like an orchid or a lamprey – like mouth, with emerald tentacles, tipped with hands emerging from within the hideous mass.

Appears as a huge, pallid, gelatinous oval with a myriad of legs and multiple eyes. Lord of the Volcano, Thoa [35]. Appears as a colossal horror with multifarious appendages, and Gorgon – like powers.

A cosmic-entity manifesting as a gigantic, spongy, and fleshy mass covered in a myriad of both eyes and spines. He is said to be the nemesis of the Outer God Uvhash, usually summoned to contrast this deity.

Appears as a giant three-eyed slug with metallic spines, and tiny pyramid-like feet underneath. Usually manifests through a Dionysian sculpture, but its true form is that of a gigantic wattled slug – thing.

Appears as a colossal pillar of amorphous alien flesh, with a cyclopean head. It drags up the continent it is summoned in, and causes the entire world to suddenly cave-in on itself. A vaporous red entity haunting the rainforest of Central Africa.

It has the power to turn humans into zombie – like servants, the Tree-Men of M’bwa. A gigantic entity dwelling in some reverse dimension, resembling a huge bullet with a long proboscis.

Appears as a gigantic, black, toad – like creature with an impossibly malevolent glare, or a tentacled, scaled, bat-winged entity. An entity cut in ten pieces by Yig during a time of great battle one of these pieces is an alabaster dish found in Egypt, dated back 1, BC.

It resembles and has a similar domain as the Greek god Bacchus. A sentient plant – like entity dwelling within a series of subterranean caverns, where it is always served by mutant rabbit-like worshipers.

A monstrous bird – like fiend with sharp teeth, dwelling beneath Antarctica, vaguely resembling an extinct pterosaur. A destructive entity manifesting as a ravenous metallic vortex.

He seems to be another half-brother of Cthulhu, like Hastur, and related to the slug-like Glaaki as well. He has also been called a “son of Yog-Sothoth “. Whether these titles are literal or conceal some dark truth about the Destroyer, none can ascertain.

He dwells somewhere in the Pleiades stellar region, and when summoned, he brings devastation. A shadowy incorporeal entity dwelling in the Dreamlands. A great shadow thing, with two glaring red eyes, able to transform the skull of its victims into green glowing stones carved with strange symbols.

A tentacled amoebic horror with multiple eyes, orifices, and a dangling gland forming a hideous face. His true form is unknown, but usually manifests either as a polypous, ravenous floating mass endowed with tentacles, drills, and suckers, or more frequently, as the King in Yellow, a humanoid being wearing tattered, yellow clothes and a mask hiding the face.

He is said to be Cthulhu ‘s half – brother. He is said to be of the air element opposed to Cthulhu’s water element. A towering greenish trunk with a “crown” of tentacles, a row of multiple eyes, and a series of additional lateral grasping appendages.

Lesser brother of Cthulhu, manifesting as a gigantic mouth surrounded by countless tentacles, similar to a titanic sea anemone. Has a spheroid body, elongated arms, short legs, and a pendulum – like head dangling underneath.

He is the brother of Ghisguth, and uncle of Tsathoggua. A gigantic, pale, worm – like horror dwelling beneath the crust of the star Xoth. She has been Cthulhu ‘s first bride, and with him spawned three sons – Ghatanothoa, Ythogtha, and Zoth-Ommog – and a younger daughter, Cthylla.

A levitating, sinuous glowing creature. A cat – like deity, similar to Bastet, but vicious and malignant. Her sister is the sylvan Lythalia. A gigantic, corpse-like human, with webbed feet and glowing red eyes.

A crustacean – like, tentacled, half-amorphous marine horror which serves Cthulhu, dwelling in the depths of the Bay of Rhiiklu, somewhere within the eastern coast of the United States.

The Ravenous One [40].

Model:sv4 reset sm@rt for android

A tni Step 5: The preparation of claim 86, wherein Y is O. It cannot endure sunlight, and eludes it by tunneling deep underneath the roots of oak trees. The compound of claim, wherein at least one of R1 and R2 is provided in formula IV below wherein x is an integer from 1 to 8; and y is an integer from 1 The compound of claim, wherein at least one of R3 and R4 is provided in formula II below wherein x is an integer from 1 to 8; and y is an integer from The association complex of claim, wherein the gene of interest is KSP eg5.

Oncogene amplification in medulloblastoma: Semin Oncol ; Ialdagorth The Dark Devourer is both the cousin and servant of Azathoth, appearing as a black, shapeless, malevolent mist. Telomestatin is a potent telomere maintenance-disabling drug in cervical carcinoma, breast cancer, multiple myeloma, leukemia, and neuroblastoma cells 11 —

To that ch1oroace ddehyde dinie;hylaweta; f fA:: The Star Mother appears as a chunk of yellow-green stone about the size of an infant. NMH2 may play an indirect role in transcriptional activation of c-myc gene expression but does not cleave the nuclease hypersensitive element III1.

See…

523 524 525 526 527

 

The reset sm@rt model:sv4 for android

Lovecraft’s “The Hoard of Wizard-Beast” Preparation of compound MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. A tentacled horror similar to a Sun Star, but endowed with branching tentacles, spines, myriads of blue glaring eyes, and gaping-maws. See…

(c) 2017 http://sawron. com. Theme: / and Http://sawron. com/.

Related posts

Leave a Comment